Can a Wasp Venom-Inspired Peptide Stop Seizures?

NOR-1202 showed route-dependent antiepileptic effects. Direct brain injection (intracerebroventricular) protected against pilocarpine-induced generalized seizures and mortality. In the kainic acid model, it improved survival but did not prevent seizures. Systemic administration (subcutaneous or intraperitoneal) showed no antiepileptic activity, suggesting the peptide cannot cross the blood-brain barrier. In a chronic temporal lobe epilepsy model, NOR-1202 did not significantly reduce spontaneous recurrent seizures.

Animal study using male mice in three seizure models: acute pilocarpine-induced, acute kainic acid-induced, and chronic temporal lobe epilepsy (pilocarpine). NOR-1202 was administered via intracerebroventricular injection (using stereotaxic surgery), subcutaneous, or intraperitoneal routes at various doses.

Current antiepileptic drugs often fail for temporal lobe epilepsy and cause significant side effects. Venom-derived peptides represent a novel class of potential neurological therapeutics. While NOR-1202's inability to work systemically limits its current utility, understanding its brain-level mechanism could guide development of modified versions that cross the blood-brain barrier.

Venoms are rich sources of bioactive peptides that evolution has optimized to affect nervous system function. Mining venom peptides for neurological therapeutics is a growing field, though the blood-brain barrier remains a major challenge for peptide drug delivery.

Animal study only — no human data. The peptide's inability to work when given systemically is a major limitation for clinical development. Only male mice were used, limiting generalizability. Small sample sizes typical of animal studies. The chronic epilepsy model showed no benefit, raising questions about efficacy in established epilepsy.